Inactive Instrument

XTL Biopharmaceuticals Ltd. TEL AVIV STOCK EXCHANGE

Equities

XTLB

IL0010854979

Biotechnology & Medical Research

XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021

March 30, 2022 at 05:14 pm EDT

XTL Biopharmaceuticals Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net income was USD 0.435 million compared to net loss of USD 2.95 million a year ago. Basic earnings per share from continuing operations was USD 0.001 compared to basic loss per share from continuing operations of USD 0.006 a year ago.

Latest news about XTL Biopharmaceuticals Ltd.

Top Midday Gainers	Mar. 20	MT
XTL Biopharmaceuticals to Acquire The Social Proxy; Shares Soar	Mar. 20	MT
XTL Biopharmaceuticals Ltd. entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd. for $0.43 million.	Mar. 19	CI
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
XTL Biopharmaceuticals Ltd. Elects Alexander Rabinovitch as Directors	17-08-03	CI
XTL Biopharmaceuticals Appoints Alex Rabinovich to its Board of Directors	17-04-27	CI
XTL Biopharmaceuticals Ltd. Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome	17-04-05	CI
XTL Biopharmaceuticals Ltd. Announces Resignation David Kestenbaum as Chief Financial Officer	17-04-04	CI
XTL Biopharmaceuticals Ltd. Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2016	17-03-30	CI
XTL Biopharmaceuticals Ltd. announced that it has received $2.8 million in funding	17-03-21	CI
XTL Biopharmaceuticals Ltd. announced that it expects to receive $2.8 million in funding	17-03-06	CI
XTL Biopharmaceuticals Ltd. Announces Appointments to its Clinical Advisory Board	17-02-13	CI
XTL Biopharmaceuticals Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	16-12-06	CI
XTL Biopharmaceuticals Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	16-09-27	CI
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1	16-08-11	CI
XTL Biopharmaceuticals Ltd. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2016	16-06-01	CI

Chart XTL Biopharmaceuticals Ltd.

Duration

Period

More charts

Company Profile

XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.81%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research